TY - JOUR
T1 - Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
AU - Heijerman, Harry
AU - Westerman, Elsbeth
AU - Conway, Steven
AU - Touw, Daan
AU - Döring, Gerd
AU - Høiby, Niels
AU - consensus working group
N1 - Keywords: Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchodilator Agents; Cystic Fibrosis; Drug Combinations; Expectorants; Humans; Lung Diseases; Nebulizers and Vaporizers; Respiratory System Agents
PY - 2009
Y1 - 2009
N2 - In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.
AB - In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.
U2 - 10.1016/j.jcf.2009.04.005
DO - 10.1016/j.jcf.2009.04.005
M3 - Journal article
C2 - 19559658
SN - 1569-1993
VL - 8
SP - 295
EP - 315
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 5
ER -